|View printer-friendly version|
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
- Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004
Under the terms of the amended agreement, ASLAN will make a first payment of
ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1. By targeting IL-13Rα1, ASLAN004 potently inhibits signalling of both interleukin 4 (IL-4) and interleukin 13 (IL-13), which are central to triggering symptoms of allergy in atopic dermatitis. ASLAN is currently conducting a phase 1 clinical trial in healthy volunteers investigating ASLAN004 as a treatment for atopic dermatitis. Recently announced data from the first part of the study demonstrated that ASLAN004 was safe and well tolerated at all doses when administered intravenously. Analysis of downstream mediators including phosphorylation of STAT6, a critical mediator of allergic inflammation, demonstrated complete inhibition within one hour of dosing, which was then maintained for more than 29 days. ASLAN expects to report data from the second part of the study, testing a subcutaneous formulation, shortly and intends to initiate a multiple ascending dose study in moderate to severe atopic dermatitis patients in the second half of 2019.
Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide1, characterized by red inflamed skin and severe daytime and night-time itching, which can severely impact patients’ quality of life. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.
Media and IR contacts
ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a best-in-class therapy. By targeting IL-13Rα1, ASLAN004 potently inhibits signalling of both interleukin 4, or IL-4, and interleukin 13, or IL-13. IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, exacerbations of disease, wheezing and coughing.
Forward looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited